MannKind reported $9.75M in EBITDA for its fiscal quarter ending in June of 2025.


Ebitda Change Date
Adma Biologics USD 43.99M 3.58M Jun/2025
Dynavax Technologies USD -21594000 22.03M Mar/2025
Eli Lilly USD 7.5B 3.34B Jun/2025
Halozyme Therapeutics USD 225.5M 63.51M Jun/2025
Insmed USD -297127000 71.11M Jun/2025
MacroGenics USD -33437000 17.35M Jun/2025
MannKind USD 9.75M 17.66M Jun/2025
Merck USD 7.74B 625M Mar/2025
Novo Nordisk DKK 46.05B 10.07B Mar/2025
Pfizer USD 5.32B 889M Jun/2025
Sanofi EUR 1.89B 971M Jun/2025
Xencor USD -30519000 6.39M Jun/2025